Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2011 1
2016 1
2017 3
2019 5
2020 5
2021 2
2022 4
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic Footprints and Molecular Subtypes in Breast Cancer.
Cappelletti V, Iorio E, Miodini P, Silvestri M, Dugo M, Daidone MG. Cappelletti V, et al. Among authors: silvestri m. Dis Markers. 2017;2017:7687851. doi: 10.1155/2017/7687851. Epub 2017 Dec 24. Dis Markers. 2017. PMID: 29434411 Free PMC article. Review.
A gene expression-based classifier for HER2-low breast cancer.
Di Cosimo S, Pizzamiglio S, Ciniselli CM, Duroni V, Cappelletti V, De Cecco L, De Marco C, Silvestri M, De Santis MC, Vingiani A, Paolini B, Orlandi R, Iorio MV, Pruneri G, Verderio P. Di Cosimo S, et al. Among authors: silvestri m. Sci Rep. 2024 Feb 1;14(1):2628. doi: 10.1038/s41598-024-52148-7. Sci Rep. 2024. PMID: 38297001 Free PMC article.
Can we define breast cancer HER2 status by liquid biopsy?
Di Cosimo S, De Marco C, Silvestri M, Busico A, Vingiani A, Pruneri G, Cappelletti V. Di Cosimo S, et al. Among authors: silvestri m. Int Rev Cell Mol Biol. 2023;381:23-56. doi: 10.1016/bs.ircmb.2023.07.003. Epub 2023 Sep 4. Int Rev Cell Mol Biol. 2023. PMID: 37739483 Review.
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.
Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, Verzoni E, Di Cosimo S, Locati LD, Cristofanilli M, Daidone MG, Cappelletti V. Reduzzi C, et al. Among authors: silvestri m. Semin Cancer Biol. 2020 Feb;60:344-350. doi: 10.1016/j.semcancer.2019.10.008. Epub 2019 Oct 15. Semin Cancer Biol. 2020. PMID: 31626958 Free article. Review.
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.
De Mattia E, Silvestri M, Polesel J, Ecca F, Mezzalira S, Scarabel L, Zhou Y, Roncato R, Lauschke VM, Calza S, Spina M, Puglisi F, Toffoli G, Cecchin E. De Mattia E, et al. Among authors: silvestri m. Biomed Pharmacother. 2022 Oct;154:113644. doi: 10.1016/j.biopha.2022.113644. Epub 2022 Sep 2. Biomed Pharmacother. 2022. PMID: 36063648 Free PMC article.
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S, Ciniselli CM, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez HL, Iorio MV, Vingiani A, Pruneri G, Verderio P. Di Cosimo S, et al. Among authors: silvestri m. Front Oncol. 2023 Jan 31;12:1028825. doi: 10.3389/fonc.2022.1028825. eCollection 2022. Front Oncol. 2023. PMID: 36798690 Free PMC article.
26 results